Table 1 Demographic, clinical and laboratory characteristics of the patients’ cohort
From: Time course of lung ultrasound findings in patients with COVID-19 pneumonia and cardiac dysfunction
Parameter | CD+ | CD− | p value |
|---|---|---|---|
Gender F/M (n) | 16/6 (22) | 12/17 (29) | 0.02 |
Age, median (IQR) | 69 (54–79) | 59 (49–70) | 0.03 |
Obesity, n (%) | 10 (46) | 10 (35) | > 0.1 |
Hypertension, n (%) | 12 (55) | 21 (72) | > 0.1 |
Diabetes mellitus, n (%) | 5 (23) | 13 (44) | > 0.1 |
Ischemic cardiac disease, n (%) | 1 (5) | 5 (17) | > 0.1 |
Days since onset of symptoms, median (IQR) | 5 (3–6) | 5 (3–8) | > 0.1 |
Lymphocytes (cells/L), median (IQR) | 755 (595–1200) | 980 (685–1680) | 0.04 |
Neutrophils/lymphocytes ratio, median (IQR) | 8 (7–10) | 6 (3–8) | > 0.1 |
CRP (mg/dl), median (IQR) | 12 (8–18) | 8 (4–13) | 0.06 |
ESR (mm per hour), median (IQR) | 120 (74–120) | 109 (82–120) | > 0.1 |
Ferritin (ng/mL), median (IQR) | 905 (670–1275) | 791 (490–1370) | > 0.1 |
Troponin (ng/mL), median (IQR) | 13(13–23) | 13(13–26) | > 0.1 |
NT-proBNP (pg/mL), median (IQR) | 205(69–686) | 275(89–980) | > 0.1 |
Admitted in ICU, n (%) | 19 (86) | 11 (38) | 0.004 |
Invasive mechanical ventilation, n (%), median in days (IQR) | 7 (32), 6 (5–17) | 1 (3), 16 | > 0.1 |
Treatment, n (%) Methylprednisolone | 19 (86) | 20 (69) | 0.03 |
ICU length of stay in days, median (IQR) | 12 (8–18) | 11 (8–22) | > 0.1 |
Hospital length of stay in days, median (IQR) | 12 (10–20) | 17 (8–28) | > 0.1 |
Mortality, n (%) 30 days mortality, n (%) | 1 (5) 1 (5) | 7 (24) 8 (28) | > 0.1 > 0.1 |